Figure S1


Sae2-like domain
S327
PLDLS
T847
T859
human
CtIP
coiled coil
897 amino acids
S326
PLDLS
T843
T855
mouse
Ctip
coiled coil
893
S328
PLDLS
T806
T818
frog
xCtIP
coiled coil
856
S267
T279
S. cerevisiae
Sae2
345

Figure S2a-d


a
Ctip^wt
H3
RV
B2
T855
BstXI
B2
XhoI
SacI
H3
exon 16
17
18
19
b
targeting construct
PmeI
RV
B2
T855A
B2
XhoI
NotI
neo
exon 16
17
18
19
H3
Bam
c
Ctip^T855A-neo
H3
RV
B2
T855A
B2
XhoI
SacI
H3
neo
exon 16
17
18
19
H3
Bam
5'-probe
3'-probe
d
Ctip^T855A
H3
RV
B2
T855A
B2
Xho
Sac
H3
exon 16
17
18
19
H3
Bam
5'-probe
3'-probe

Point mutant validation of Ctip-T885A/T855A Mefs:

Figure S2e



Figure S2f


ctip-19
EXON 18
T855A
(ACT→GCT)
SspI (432)
EcoRI (527)
AccI (617)
BstNI (628)
ctip-20
ctip-0

Figure S3a


a
MEF clone
+/+ (1)
TA/TA (4)
TA/TA (2)
TA/+ (5)
+/+ (11)
TA/TA (12)
TA/+ (13)
Kd
– + – + – + – + – + – + – +
CPT
150 –
– Ctip
50 –
– α-tubulin

Figure 3b-e


b
% of control survival
100
10
1
0.0
0.5
1.0
1.5
2.0
2.5
Olaparib (µM)
Ctip+/+ (3)
Ctip+/+ (1)
CtipTA/+ (5)
CtipTA/+ (6)
CtipTA/TA (4)
CtipTA/TA (2)
c
% of control survival
100
10
1
0
1
2
3
4
UV (J/m2)
Ctip+/+ (1)
CtipTA/+ (5)
CtipTA/TA (4)
CtipTA/TA (2)
d
% of control survival
100
10
1
0
1
2
3
4
HU (mM)
Ctip+/+ (1)
CtipTA/+ (5)
CtipTA/TA (4)
CtipTA/TA (2)
e
% of control survival
100
10
1
0
50
100
150
200
NCS (ng/ml)
Ctip+/+ (1)
CtipTA/+ (5)
CtipTA/TA (4)
CtipTA/TA (2)

Figure S3f

f


100
10
1
% of control survival
0.0
1.0
2.0
3.0
4.0
5.0
Etoposide (μM)
Ctip+/+ (1)
CtipTA/+ (5)
CtipTA/TA (4)
CtipTA/TA (2)